Liquid Biopsy Technology and its Impacts on Insurance

Dr. Daniel D. Zimmerman
Dr. Heather M. Lund
Andrew Gaskell

In Brief

Curious about RGA's medical insights? Contact us to learn more.

This video was developed in conjunction with actuview, the first permanent international media platform for actuaries (www.actuview.com). actuview content reflects contributions from actuarial institutions, corporate partners and industry professionals. RGA is actuview’s sponsoring partner.

When it comes to cancer diagnosis, are liquid biopsies too good to be true – or right over the horizon?

RGA's Dan Zimmerman, Heather Lund and Andrew Gaskell explore the current clinical applications and future potential of liquid biopsy technologies. These simple blood tests promise to be far less intrusive, improving the patient experience and outcomes.

Perhaps most important, liquid biopsies offer a powerful path to multi-cancer early detection. The tests have the potential to identify between 50 to 100 types of cancers that currently lack screens. Many are most often diagnosed at very late stages when the patient presents with symptoms, and the mortality outcomes are poor as a result.

RGA's experts provide an insurance perspective, delving into challenges from anti-selection to overdiagnosis and discussing product design considerations. Liquid biopsies seem likely to revolutionize oncology, and insurers must take care to fully understand this technology and its implications.

At RGA, we are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to discuss and learn more about the RGA capabilities, resources, and solutions.